Tag: Stembiosys

StemBioSys Announces Launch of CELLvo™ Atrial Cardiomyocyte, a Technological Leap Forward in Cardiotoxicity Screening

Coronary/Structural Heart by 0 comments

Developed in collaboration with REPROCELL, CELLvo™ Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells SAN ANTONIO, June 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to […]

Continue Reading →

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

Coronary/Structural Heart by 0 comments

Matrix Plus promotes functional and structural maturation of hiPSC-CMs in seven days compared to partial maturation obtained within 30 to 100 days with current approaches SAN ANTONIO and ANN ARBOR, Mich., Nov. 9, 2020 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix […]

Continue Reading →